Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2007

Open Access 01-12-2007 | Review

Intermittent preventive treatment for malaria in pregnancy in Africa: What's new, what's needed?

Authors: Andrew Vallely, Lisa Vallely, John Changalucha, Brian Greenwood, Daniel Chandramohan

Published in: Malaria Journal | Issue 1/2007

Login to get access

Abstract

Falciparum malaria is an important cause of maternal, perinatal and neonatal morbidity in high transmission settings in Sub-Saharan Africa. Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP-IPT) has proven efficacious in reducing the burden of pregnancy-associated malaria but increasing levels of parasite resistance mean that the benefits of national SP-IPT programmes may soon be seriously undermined in much of the region. Hence, there is an urgent need to develop alternative drug regimens for IPT in pregnancy. This paper reviews published safety and efficacy data on various antimalarials and proposes several candidate combination regimens for assessment in phase II/III clinical trials.
Literature
1.
Breman JG, Alilio MS, Mills A: Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg. 2004, 7(Suppl 2): 1-15.
2.
Schellenberg D, Armstrong-Schellenberg JRM, Mushi A, de Savigny D, Mgalula L, Mbuya C, Victora CG: The silent burden of anaemia in Tanzanian children: a community based study. Bull World Health Organ. 2003, 81 (8): 581-590.PubMedCentralPubMed
3.
Shulman CE, Graham WJ, Jilo H, Lowe BS, New L, Obiero J, Snow RW, Marsh K: Malaria as an important cause of anemia in primigravidae: evidence from a district hospital in coastal Kenya. Trans R Soc Trop Med Hyg. 1996, 90: 535-539. 10.1016/S0035-9203(96)90312-0.PubMed
4.
Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG: Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine . Am J Trop Med Hyg. 1996 , 55 (1 Suppl): 50-56.PubMed
5.
Marchant T, Armstrong-Schellenberg J, Nathan R, Abdulla S, Mukasa O, Mshinda H, Lengeler C: Anaemia in pregnancy and infant mortality in Tanzania. Trop Med Int Health. 2004, 9 (2): 262-266. 10.1046/j.1365-3156.2003.01178.x.PubMed
6.
Diagne N, Rogier C, Sokhna CS, Tall A, Fontenille D, Roussilhon C, Spiegel A, Trape JF: Increased susceptibility to malaria during the early post-partum period. N Eng J Med. 2000 , 343 (9): 598-603. 10.1056/NEJM200008313430901.
7.
Vallely L, Ahmed Y, Murray SF: Postpartum maternal morbidity requiring hospital admission in Lusaka, Zambia-a descriptive study. ,. BMC Pregnancy Childbirth. 2005, 5 (1):
8.
Ramharter M, Grobusch MP, Kiessling G, Adegnika AA, Moller U, Agnandji ST, Kramer M, Schwarz N, Kun JF, Oyakhirome S, Issifou S, Borrmann S, Lell B, Mordmuller B, Kremsner PG: Clinical and parasitological characteristics of puerperal malaria. J Inf Dis. 2005, 191 (6): 1005-1009. 10.1086/427781.
9.
Ayisi JG, van Eijk AM, ter Kuile FO, Kolczak MS, Otieno JA, Misore AO, Kager PA, Steketee RW, Nahlen BL: The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya. AIDS. 2003, 17 (4): 585-594. 10.1097/00002030-200303070-00014.PubMed
10.
Ladner J, Leroy V, Simonon A, Karita E, Bogearts J, De Clercq A, Van De Perre P, Dabis F, and the Pregnancy and HIV Study Group: HIV infection, malaria and pregnancy: a prospective cohort study in Kigali, Rwanda. Am J Trop Med Hyg. 2002, 66 (1): 56-60.PubMed
11.
Steketee RW, Wirima JJ, Bloland PB, Chilima B, Mermin JH, Chitsulo L, Breman JG: Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg. 1996, 55 (1 Suppl): 42-49.PubMed
12.
Brahmbhatta H, Kigozib G, Wabwire-Mangenc F, Serwadda D, Sewankamboc N, Lutalob T, Wawerd MJ, Abramowskye C, Sullivana D, Graya R: The effects of placental malaria on mother-to-child HIV transmission in Rakai, Uganda. AIDS. 2003, 17: 2539–2541-
13.
Adam T, Lim SS, Mehta S, Buhta ZA, Fogstad H, Mathai M, Zupan J, Darmstadt GL: Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries. BMJ. 2005, 331: 1107-1110. 10.1136/bmj.331.7525.1107.PubMedCentralPubMed
14.
Evans DB, Adam T, Edejer T, Lim SS, Cassels A, Evans TG: Time to reassess strategies for improving health in developing countries. BMJ. 2005, 331: 1133-1136. 10.1136/bmj.331.7525.1133.PubMedCentralPubMed
15.
Sanders DM, Todd C, Chopra M: Confronting Africa's health crisis: more of the samewill not be enough. BMJ. 2005, 331: 755-758. 10.1136/bmj.331.7519.755.PubMedCentralPubMed
16.
Nahlen BL: Rolling Back Malaria. N Eng J Med. 2000, 343: 651-652. 10.1056/NEJM200008313430909.
17.
WHO: A Strategic Framework for Malaria Prevention and Control during Pregnancy in the Africa Region. 2004, World Health Organization Regional Office for Africa
18.
Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts J, Misore A, Muga R, Oloo AJ, Steketee RW: Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg. 1998, 59 (5): 813-822.PubMed
19.
Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, Peshu N, Marsh K: Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet. 1999, 353: 632-636. 10.1016/S0140-6736(98)07318-8.PubMed
20.
Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitsulo L, Wirima JJ: The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg. 1994, 51 (5): 515-522.PubMed
21.
Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Russel WB, Broadhead RL: An evaluation of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birth weight in rural Malawi. Ann Trop Med Parasitol. 1998, 92: 141-150. 10.1080/00034989859979.PubMed
22.
Schultz LJ, Steketee RW, Chitsulo L, Wirima JJ: Antimalarials during pregnancy: a cost-effectiveness analysis. Bull WHO. 1995, 73 (2): 207-214.PubMedCentralPubMed
23.
EANMAT: The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health. 2003, 8 (10): 860-867. 10.1046/j.1360-2276.2003.01114.x.
24.
Newman RD, Moran AC, Kayentao K, Benga-De E, Yameogo M, Gaye O, Faye O, Lo Y, Moreira PM, Duombo O, Parise ME, Steketee RW: Prevention of malaria during pregnancy in West Africa: policy change and the power of subregional action. Trop Med Int Health. 2006, 11 (4): 462-469. 10.1111/j.1365-3156.2006.01593.x.PubMed
25.
Hill J, Kazembe P: Reaching the Abuja target for intermittent preventive treatment of malaria in pregnancy in African women: a review of progress and operational challenges. Trop Med Int Health. 2006, 11 (4): 409-418. 10.1111/j.1365-3156.2006.01585.x.PubMed
26.
Plowe CV, Kublin JG, Dzinjalamala FK, Kamwendo DS, Mukadam RA, Chimpeni P, Molyneux ME, Taylor TE: Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. BMJ. 2004, 328 (6): 545-548. 10.1136/bmj.37977.653750.EE.PubMedCentralPubMed
27.
28.
Ringwald P: Treatment failure and resistance in Malawi remain subject for debate. BMJ. 2004, 328: 1259-10.1136/bmj.328.7450.1259-a.PubMedCentralPubMed
29.
Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, Falade COF, Horton J, Jaffar S, Kanyok T, Kremsner PG, Kublin JGL, Missinou MA, Mkandala C, Oduola AMJ, Premji Z, Robertson L, Sowumni A, Ward SA, Winstanley PA: Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double blind randomized controlled trial. Lancet. 2004, 363: 1843-1848. 10.1016/S0140-6736(04)16350-2.PubMed
30.
Jima D, Tesfaye G, Medhin A, Kebede A, Argaw D, Babaniyi O: Efficacy of sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J. 2005, 82 (8): 391-395.PubMed
31.
Zurovac D, Ndhlovu M, Rowe AK, Hamer DH, Thea DM, Snow RW: Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross-sectional study. BMJ. 2005, 331: 734-737. 10.1136/bmj.331.7519.734.PubMedCentralPubMed
32.
33.
Campbell P, Baruah S, Narauin K, Rogers CC: A randomised trial comparing the efficacy of four treatment regimens for uncomplicated falciparum malaria in Assam state, India. Trans R Soc Trop Med Hyg. 2006, 100 (2): 108-118. 10.1016/j.trstmh.2005.06.016.PubMed
34.
van den Broek IV, Maung UA, Peters A, Liem L, Kamal M, Rahman M, Rahman MR, Bangali AM, Das S, Barends M, Faiz AM: Efficacy of chloroquine + sulfadoxine--pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh. Trans R Soc Trop Med Hyg. 2005, 99 (10): 727-735. 10.1016/j.trstmh.2005.02.007.PubMed
35.
McIntosh HM, Jones KL: Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. Cochrane Database Syst Rev. 2005, 4: CD000386-PubMed
36.
37.
Phillips-Howard PA, Stefen R, Kerr L, Vanhauwere B, Fuchs E, Edwards R: Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med. 1998, 5: 121-126. 10.1111/j.1708-8305.1998.tb00484.x.PubMed
38.
Schlagenhauf P: Mefloquine for malaria chemoprophylaxis 1992-1998: A review. J Travel Med. 1999, 6 (2): 122-133.PubMed
39.
Vanhauwere B, Maradit H, Kerr L: Post-marketing surveillance of prophylactic mefloquine (Larium) use in pregnancy. Am J Trop Med Hyg. 1998, 58 (1): 17-21.PubMed
40.
Garner P, Brabin B: A review of randomized controlled trials of routine antimalarial drug prophylaxis during pregnancy in endemic malarious areas. Bull World Health Organ. 1994, 72 (1): 89-99.PubMedCentralPubMed
41.
Nosten F, ter Kuile F, Maelankiri L, Chongsuphajaisiddhi T: Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study , . J Infect Dis. 1994, 169: 595-603.PubMed
42.
Fleming AF, Ghatoura GB, Harrison KA, Briggs ND, Dunn DT: The prevention of anaemia in pregnancy in primigravidae in the guinea savanna of Nigeria. Ann Trop Med Parasitol. 1986, 80 (2): 211-233.PubMed
43.
Mutabingwa TK, Malle LN, de Geus A, Oosting J: Malaria chemosuppression in pregnancy. I. The effect of chemosuppressive drugs on maternal parasitaemia.Trop Geogr Med. 1993, 45 (1): 6-14.PubMed
44.
45.
46.
47.
Tagbor H, Bruce J, Browne E, Randal A, Greenwood B, Chandramohan D: Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. Lancet. 2006, 368 (1349-56):
48.
Thomas F, Erhart A, D'Alessandro U: Can amodiaquine be used safely during pregnancy?. Lancet Inf Dis. 2004, 4 (4): 235-239. 10.1016/S1473-3099(04)00974-0.
49.
Nosten F, McGready R, d'Alessandro U, Bonell A, Verhoeff F, Menendez C, Mutabingwa T, Brabin B: Antimalarial Drugs in Pregnancy: A Review. Curr Drug Safety. 2006, 1: 1-15.
50.
Orton L, Garner P: Drugs for treating uncomplicated malaria in pregnant women. Cochrane Database Syst Rev. 2005, 3: CD004912-PubMed
51.
Davis TME, Karunajeewa HA, Ilett KF: Artemisinin-combination therapies for uncomplicated malaria. Med J Aust. 2005, 184 (4): 181-185.
52.
53.
Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ: Antimalarial drug resistance, Artemisinin-based Combination Therapy and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg. 2004, 71(Suppl 2) : 179-186.
54.
Kremsner PG, Krishna S: Antimalarial combinations. Lancet. 2004, 364: 285-294. 10.1016/S0140-6736(04)16680-4.PubMed
55.
Winstanley P, Ward S, Snow R, Breckenridge A: Therapy of falciparum malaria in Sub-Saharan Africa: from molecule to policy. Clin Microbiol Rev. 2004, 17 (3): 612-637. 10.1128/CMR.17.3.612-637.2004.PubMedCentralPubMed
56.
Eyers JE: Searching bibliographic databases effectively. Health Policy Plan. 1998, 13 (3): 339-342. 10.1093/heapol/13.3.339.PubMed
57.
58.
Newman RD, Parise ME, Slutsker L, Nahlen B, Steketee RW: Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa . Trop Med Int Health. 2003, 8: 488-506. 10.1046/j.1365-3156.2003.01066.x.PubMed
59.
Roche: LARIAM (mefloquine hydrochloride): Complete product information. 2004, Nutley, New Jersey, USA , Roche Laboratories, Inc., 1-18.
60.
Smoak BL, Writer JV, Keep LW, Cowan J, Chantelois JL: The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen . J Inf Dis. 1997, 176: 831-833.
61.
Okeyeh JN, Lege-Oguntove L, Emembolu JO, Agbo M: Malaria in pregnancy: efficacy of a low dose of mefloquine in an area holoendemic for multi-resistant Plasmodium falciparum. Ann Trop Med Parasitol. 1996 , 90 (3): 265-268.PubMed
62.
Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, de Vries A, Chongsuphajaisiddhi T, White NJ: The effects of mefloquine treatment in pregnancy. Clin Inf Dis. 1999, 28: 808-815.
63.
Adam I, Ali DA, Alwaseila A, Kheir MM, Elbashir MI: Mefloquine in the treatment of falciparum malaria during pregnancy in Eastern Sudan. Saudi Med J. 2004, 25 (10): 1400-1402.PubMed
64.
Sowunmi A, Oduola AMJ, Ogundahunsi OAT, Fehintola FA, Ilesanmi OA, Akinyinka OO, Arowojolu AO: Randomised trial of artemether versus artemether and mefloquine for the treatment of chloroquine/sulfadoxine-pyrimethamine-resistant falciparum malaria during pregnancy. J Obstet Gynaecol. 1998, 18 (4): 322-327. 10.1080/01443619867038.PubMed
65.
Bounyasong S: Randomized trial of trial of artesunate and mefloquine in comparison with quinine sulphate to treat P.falciparum malaria in pregnant women. J Med Assoc Thai. 2000, 84 (9): 1289-1299.
66.
McGready R, Brockman A, Cho T, Cho D, van Vugt M, Luxemburger C, Chongsuphajaisiddhi T, White NJ, Nosten F: Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg. 2000, 94: 689-693. 10.1016/S0035-9203(00)90235-9.PubMed
67.
Bounyasong S: Randomized trial of trial of artesunate and mefloquine in comparison with quinine sulphate to treat P. falciparum malaria in pregnant women. J Med Assoc Thai. 2001, 84 (9): 1289-1299.PubMed
68.
Pfizer: Zithromax. 2004, New York, USA , Pfizer Inc, 1-32.
69.
Heikkinen T, Laine K, Neuvonen PJ, Ekblad U: The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. Br J Obstet Gynaecol. 2000, 107 (6): 770-775.
70.
Ramsey PS, Vaules MB, Vasdev GM, Andrews WW, Ramin KD: Maternal and transplacental pharmacokinetics of azithromycin. Am J Obstet Gynecol. 2003, 188 (3): 714-718. 10.1067/mob.2003.141.PubMed
71.
Donders GG: Treatment of sexually transmitted bacterial diseases in pregnant women. Drugs. 2000, 59 (3): 477-485. 10.2165/00003495-200059030-00005.PubMed
72.
Duff P: Antibiotic selection in obstetric patients. Infect Dis Clin North Am. 1997, 11 (1): 1-12. 10.1016/S0891-5520(05)70338-X.PubMed
73.
Ogasawara KK, Godwin TM: Efficacy of azithromycin in reducing lower genital Ureaplasma urealyticum colonization in women at risk for preterm delivery. J Matern Fetal Med. 1999 , 8 (1): 12-16. 10.1002/(SICI)1520-6661(199901/02)8:1<12::AID-MFM3>3.0.CO;2-8.PubMed
74.
Ohrt C, Willingmyre GD, Lee P, Knirsch C, Milhous W: Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 2002, 46 (8): 2518-2524. 10.1128/AAC.46.8.2518-2524.2002.PubMedCentralPubMed
75.
Pradines B, Rogier C, Fusai T, Mosnier J, Daries W, Barret E, Parzy D: In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron. Antimicrob Agents Chemother. 2001, 45 (6): 1746-1750. 10.1128/AAC.45.6.1746-1750.2001.PubMedCentralPubMed
76.
Andersen SL, Ager AL, McGreevy P, Schuster BG, Ellis W, Berman J: Efficacy of azithromycin as a causal prophylactic agent against murine malaria. Antimicrob Agents Chemother. 1994, 38 (8): 1862-1863.PubMedCentralPubMed
77.
Taylor WR, Richie TL, Fryauff DJ, Ohrt C, Picarima H, Tang D, Murphy GS, Widjaja H, Braitman D, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J: Tolerability of azithromycin as malaria prophylaxis in adults in North East Papua, Indonesia. Antimicrob Agents Chemother. 2003, 47 (7): 2199-2203. 10.1128/AAC.47.7.2199-2203.2003.PubMedCentralPubMed
78.
Andersen SL, Oloo AJ, Gordon DM, Ragama OB, Aleman GM, Berman JD, Tang DB, Dunne MW, Shanks GD: Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Inf Dis. 1998, 26: 146-150.
79.
Krudsood S, Silchamroon U, Wilairatana P, Singhasivanon P, Phumratanaprapin W, Chalermrut K, Phophak N, Popa C: A randomised clinical trial of combination artesunate and azithromycin for treatment of uncomplicated Plasmodium falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health. 2000, 31 (4): 801-807.PubMed
80.
WHO: Review of the safety of chlorproguanil-dapsone in the treatment of uncomplicated falciparum malaria in Africa. Report of a technical consultation convened by WHO, Geneva, 1-2 July 2004. 2005, Geneva , World Health Organization
81.
Na-Bachang K, Manyando C, Ruengweerayut R, Kioy D, Mulenga M, Miller GB, Konsil J: The pharmacokinetics and pharmacodynamics of atovoquone and proguanil for the treatment of uncomplicated facliparum malaria in third-trimester pregnant women. Eur J Clin Pharmacol. 2005, 61: 573-582. 10.1007/s00228-005-0969-7.
82.
Mutabingwa TK, Malle LN, de Geus A, Osting J: Malaria chemosuppression in pregnancy. II. Its effect on maternal haemoglobin levels, placental malaria and birth weight. Trop Geogr Med. 1993, 45 (2): 49-55.PubMed
83.
GlaxoSmithKline: MALARONE (atovaquone and proguanil hydrochloride): Prescribing Information. 2005, Research Triangle Park, NC 27709 , GlaxoSmithKline , 1-19.
84.
Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, Roskell NS, Chulay JD, and the Malarone International Study Team: Atovaquone-proguanil versus mefloquine for malaria prophylaxis in non-immune travelers: results from a randomized, double-blind study. Clin Inf Dis. 2001, 33: 1015-1021. 10.1086/322694.
85.
Looareesuwan S, Wilairatana P, Chalermarut K, Rattanapong Y, Canfield CJ, Hutchinson DBA: Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg. 1999, 60 (4): 526-532.PubMed
86.
McGready R, Ashley EA, Moo E, Cho T, Barends M, Hutagalung R, Looareesuwan S, White NJ, Nosten F: A randomised comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. J Inf Dis. 2005, 192: 846-853. 10.1086/432551.
87.
Mutabingwa TK, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, Watkins W: Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet. 2001, 358: 1218-1223. 10.1016/S0140-6736(01)06344-9.PubMed
88.
Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, Molyneux ME, Marsh K, Taylor TE, Watkins WM, Winstanley PA: Comparison of chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomized clinical trial. Lancet. 2002, 360: 1136-1143. 10.1016/S0140-6736(02)11198-6.PubMed
89.
Keuter M, van Eijk A, Hoogstrate M, Raasveld M, van de Ree B, Ngwawe WA, Watkins WM, Were JB, Brandling-Bennett AD: Comparison of chloroquine, pyrimethamine and sulfadoxine, and chlorproguanil and dapsone as treatment for falciparum malaria in pregnant and non-pregnant women, Kakamega District, Kenya. BMJ. 1990, 301 (6750): 466-470.PubMedCentralPubMed
90.
91.
92.
93.
94.
Novartis: Coartem/Riamet. Product monograph: A novel antimalarial combination: one product, two concepts. 2005, Novartis Pharma AG
95.
96.
Longo M, Zanoncelli S, Manera D, Brughera M, Colombo P, Lansen J, Mazue G, Gomes M, Taylor WR, Olliaro P: Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitro. Reprod Toxicol. 2006, 21 (1): 83-93. 10.1016/j.reprotox.2005.05.005.PubMed
97.
98.
Adam I, Ali DM, Abdalla MA: Artesunate plus sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan. Trans R Soc Trop Med Hyg. 2006, 100: 632-635. 10.1016/j.trstmh.2005.09.019.PubMed
99.
Deen JL, von Seidlein L, Pinder M, Walraven GE, Greenwood BM: The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Trans R Soc Trop Med Hyg. 2001, 95 (4): 424-428. 10.1016/S0035-9203(01)90204-4.PubMed
100.
McGready R, Cho T, Keo NK, Thwai KL, Villegas L, Looareesuwan S, White NJ, Nosten FR: Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Inf Dis. 2001, 33: 2009-2016. 10.1086/324349.
101.
McGready R, Stepniewska K, Ward SA, Cho T, Gilveray G, Looareesuwan S, White NJ, Nosten F: Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2006, 62 (5): 367-371. 10.1007/s00228-006-0118-y.PubMed
102.
Basco LK, Ringwald P: In vitro activities of piperaquine and other 4-aminoquinilones against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob Agents Chemother. 2003, 47 (4): 1391-1394. 10.1128/AAC.47.4.1391-1394.2003.PubMedCentralPubMed
103.
Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, Thwai KL, Barends M, Looareesuwan S, White NJ, Nosten F: A randomized, controlled study of a simple, once daily regimen of dihydroartemsinin-piperaquine for the treatment of uncomplicated multi-resistant falciparum malaria. Clin Inf Dis. 2005, 41: 425-432. 10.1086/432011.
104.
105.
Denis MB, Savis TME, Hewitt S, Incardona S, Nimol K, Fandeur T, Poravuth Y, Lim C, Socheat D: Efficacy and safety of dihyroartemesinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Inf Dis. 2002 , 35: 1469-1476. 10.1086/344647.
106.
Ashley EA, Krudsoos S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, Hutagalung R, Wilairatana P, Brockman A, Looareesuwan S, Nosten F, White NJ: Randomized, controlled dose-optimization studies of dihydroartemsinin-piperaquine for the treatment of uncomplicated multi-resistant falciparum malaria in Thailand. ,. J Infect Dis. 2004, 190: 1773-1782. 10.1086/425015.PubMed
107.
Hien TT, Dolecek C, Mai PP, Dung NT, Truong N, Thai LH, An DTH, Thanh TT, Stepniewska K, White NJ, Farrar J: Dihydroartemsinin-piperaquine against multi-resistant Plasmodium falciparum malaria in Vietnam: randomized clinical trial. Lancet. 2004, 363: 18-22. 10.1016/S0140-6736(03)15163-X.
108.
Koram KA, Abuaku B, Duah N, Quashie N: Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. Acta Trop. 2005, 95 (3): 194-203. 10.1016/j.actatropica.2005.06.018.PubMed
109.
Mutabingwa TK, Anthony D, Heler A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJM: Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine + artesunate and artemether-lumefantrine for out patient treatment of malaria in Tanzanian children: a four arm randomised effectiveness trial. Lancet. 2005, 365: 1474-1480. 10.1016/S0140-6736(05)66417-3.PubMed
110.
National Institutes of Health USA: Multinational, randomized, comparative study of the efficacy and safety of three therapeutic regimens: Coarsucam (artesunate + amodiaquine fixed-dose combination) administered in 1 or 2 intakes per day versus Coartem (artemether + lumefantrine) in the treatment of uncomplicated Plasmodium falciparum malaria. 2006, [http://​www.​clinicaltrials.​gov/​ct/​show/​NCT00316329?​order=​9]
111.
Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N, Jaffar S, Baiden R, Hodgson A, Binka F, Greenwood B: Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ. 2005, 331: 727-733. 10.1136/bmj.331.7519.727.PubMedCentralPubMed
112.
Cisse B, Sokhna C, Boulanger D, Milet J, Ba EH, Richardson K, Hallett R, Sutherland C, Simondon K, Simondon F, Alexander N, Gaye O, Targett G, Lines J, Greenwood B, Trape JF: Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomized, placebo-controlled, double-blind trial. Lancet. 2006, 367 (9511): 659-667. 10.1016/S0140-6736(06)68264-0.PubMed
113.
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Lankoande M, Ouedraogo JB, Rosenthal PJ: Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. Am J Trop Med Hyg. 2005, 73 (5): 826-832.PubMed
114.
Aina O, Emeka P, Agomo P, Akintonwa A: Comparative efficacy study of CQ, DHA and DHA plus mefloquine combination in children with acute uncomplicated falciparum malaria. The 4th MIM Pan-African Malaria Conference,. 2005, Yaoundé, Cameroon
115.
Auparakkitanon S, Chapoomram S, Kuaha K, Chirachariyavej T, Wilairat P: Targeting of hematin by the antimalarial pyronaridine. Antimicrob Agents Chemother. 2006, 50 (6): 2197-2200. 10.1128/AAC.00119-06.PubMedCentralPubMed
116.
117.
Liu DQ, Lin SG, Feng XP, Chen WJ, Chen PL, Wu HM, Chen C, Liu J: Study on treatment of multi-drug resistant falciparum malaria by using a combination of dihydroartemisinin and pyronaridine [Article in Chinese]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi [=Chinese Journal of Parasitology and Parasitic Diseases]. 2002, 20 (4): 193-196.
118.
Brentlinger PE, Behrens CB, Micek MA: Challenges in the concurrent management of malaria and HIV in pregnancy in sub-Saharan Africa. Lancet Inf Dis. 2006, 6 (2): 100-111. 10.1016/S1473-3099(06)70383-8.
119.
Fried M, Duffy PE: Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science. 1996, 272: 1502-1504. 10.1126/science.272.5267.1502.PubMed
120.
Beeson JG, Rogerson SJ, Cooke BM, Reeder JC, Chai W, Lawson AM, Molyneux ME, Brown GV: Adhesion of Plasodium falciparm-infected erythrocytes to hyaluronic acid in placental malaria. Nat Med. 2000, 6 (86-90):
121.
Riley EM, Schnieder G, Sambou I, Greenwood BM: Suppression of cell-mediated immune responses to malaria antigens in pregnant Gambian women. Am J Trop Med Hyg. 1989, 40 (2): 141-144.PubMed
122.
Fievet N, Cot M, Chougnet C, Maubert B, Bickii J, Dubois B, Lehesran JY, Frobert Y, Migot F: Malaria and pregnancy in Cameroonian primigravidae-humoral and cellular immune responses to Plasmodium falciparum blood-stage antigens. Am J Trop Med Hyg. 1995, 53: 612-617.PubMed
123.
Fievet N, Cot M, Ringwald P, Bickii J, Dubois B, Le Hesran JY, Migot F, Deloron P: Immune response to Plasmodium falciparum antigens in Cameroonian primigravidae: evolution after delivery and during second trimester. Clin Exp Immunol. 1997, 107 : 462-467. 10.1046/j.1365-2249.1997.d01-966.x.PubMedCentralPubMed
124.
O'Meara WP, Breman JG, McKenzie FE: The promise and potential challenges of intermittent preventive treatment for malaria in infants (IPTi). Malar J. 2005, 4 (33):
125.
Roche: Fanisdar brand of sulfadoxine and pyrimethamine tablets: Complete product information. 2004, Nutley, New Jersey, USA , Roche Laboratories, Inc.
126.
Mutabingwa TK: Artemisinin-based combination therapies (ACTs): Best hope for malaria treatment but inaccessible to the needy!. Acta Trop. 2005, 95 (3): 305-315. 10.1016/j.actatropica.2005.06.009.PubMed
127.
Wilkinson D, Abdool Karim SS, Harrison A, Lurie M, Colvin M, Connolly C, Sturm AW: Unrecognized sexually transmitted infections in rural South African women: A hidden epidemic. Bull World Health Organ. 1999, 77 (1): 22-28.PubMedCentralPubMed
128.
Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, MacDonald KS, Maclean IW, Bwayo JJ, Temmerman M, Ronald AR, Moses SKHIVSG: Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA. 2004, 291 (21): 2555-2562. 10.1001/jama.291.21.2555.PubMed
129.
Rastogi S, Kapur S, Salhan S, Mittal A: Chlamydia trachomatis infection in pregnancy: risk factor for an adverse outcome. Br J Biomed Sci. 1999, 56 (2): 94-98.PubMed
130.
Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ: Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother. 2000, 44 (6): 1680-1685. 10.1128/AAC.44.6.1680-1685.2000.PubMedCentralPubMed
131.
Ranque S, Badiaga S, Delmont J, Brouqui P: Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections. Malar J. 2002, 1: 13-10.1186/1475-2875-1-13.PubMedCentralPubMed
Metadata
Title
Intermittent preventive treatment for malaria in pregnancy in Africa: What's new, what's needed?
Authors
Andrew Vallely
Lisa Vallely
John Changalucha
Brian Greenwood
Daniel Chandramohan
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2007
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-6-16

Other articles of this Issue 1/2007

Malaria Journal 1/2007 Go to the issue

Research

Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications

Research

Self-reported use of anti-malarial drugs and health facility management of malaria in Ghana

Research

Large-scale malaria survey in Cambodia: Novel insights on species distribution and risk factors

Research

Does the spillage of petroleum products in Anopheles breeding sites have an impact on the pyrethroid resistance?

Research

Is chloroquine chemoprophylaxis still effective to prevent low birth weight? Results of a study in Benin

Methodology

The use of fluorescence enhancement to improve the microscopic diagnosis of falciparum malaria

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits